Literature DB >> 21883385

Pre-hypertension: how low to go and do drugs have a role?

Gordon McInnes1.   

Abstract

People with pre-hypertension (high blood pressure but below the conventional threshold for intervention with antihypertensive drugs) undoubtedly have increased risk of cardiovascular and other complications. However, the vast majority has low absolute risk and whether treatment would be beneficial is uncertain. While pharmacotherapy has attractions from a public health perspective, clinicians and crucially those with pre-hypertension require robust evidence that drug treatment will lead to short term as well as long term gains. Any changes in recommendations should await adequately powered outcome studies which provide solid evidence of the magnitude of absolute risk reduction in treating pre-hypertension and assessment of the cost-effectiveness.
© 2011 The Author. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21883385      PMCID: PMC3269577          DOI: 10.1111/j.1365-2125.2011.04092.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  50 in total

1.  Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve.

Authors:  Alberto Zanchetti
Journal:  Eur Heart J       Date:  2010-10-27       Impact factor: 29.983

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data.

Authors:  Florent Boutitie; François Gueyffier; Stuart Pocock; Robert Fagard; Jean Pierre Boissel
Journal:  Ann Intern Med       Date:  2002-03-19       Impact factor: 25.391

4.  Impact of high-normal blood pressure on the risk of cardiovascular disease.

Authors:  R S Vasan; M G Larson; E P Leip; J C Evans; C J O'Donnell; W B Kannel; D Levy
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

5.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Authors:  F M Sacks; L P Svetkey; W M Vollmer; L J Appel; G A Bray; D Harsha; E Obarzanek; P R Conlin; E R Miller; D G Simons-Morton; N Karanja; P H Lin
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

6.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

9.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  3 in total

1.  Editors' pick 2012.

Authors:  Lionel D Lewis; Andrew Somogyi; Yoon K Loke; Albert Ferro; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  I Brazilian position paper on prehypertension, white coat hypertension and masked hypertension: diagnosis and management.

Authors:  Alexandre Alessi; Andréa Araujo Brandão; Annelise Machado Gomes de Paiva; Armando da Rocha Nogueira; Audes Feitosa; Carolina de Campos Gonzaga; Celso Amodeo; Decio Mion; Dilma do Socorro Moraes de Souza; Eduardo Barbosa; Emilton Lima Junior; Fernando Nobre; Flavio Dani Fuchs; Hilton Chaves Junior; Jamil Cherem Schneider; João Gemelli; José Fernando Villela-Martin; Luiz Cesar Nazario Scala; Marco Antonio Mota Gomes; Marcus Vinicus Bolivar Malachias; Nelson Siqueira de Morais; Osni Moreira Filho; Oswaldo Passarelli Junior; Paulo Cesar Brandão Veiga Jardim; Roberto Dischinger Miranda; Rui Póvoa; Sandra Cristina Fuchs; Sergio Baiocchi; Thiago Veiga Jardim; Weimar Kunz Sebba Barroso
Journal:  Arq Bras Cardiol       Date:  2014-02       Impact factor: 2.000

3.  Relevance of prehypertension as a diagnostic category in asymptomatic adults.

Authors:  Fernando Costa Nary; Raul D Santos; Antonio Gabriele Laurinavicius; Raquel Dilguerian de Oliveira Conceição; José Antonio Maluf de Carvalho
Journal:  Einstein (Sao Paulo)       Date:  2013 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.